From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS

Cancer

Volumn 119, Issue 23, 2013, Pages 4083-4085

  Vauthey, Jean Nicolas ^a   Kopetz, Scott E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; OXALIPLATIN; RAS PROTEIN;

CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; DISEASE FREE SURVIVAL; EDITORIAL; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LIVER SURGERY; ONCOGENE K RAS; ONCOGENE RAS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME;

BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84888013791     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28348     Document Type: Editorial

References (20)

1. Karagkounis G, Torbenson M, Daniel HB, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013; 119: 4137-4144.
2. Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011; 29: 1083-1090.
3. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27: 3677-3683.
4. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996; 77: 1254-1262.
5. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309-318.
6. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008; 247: 125-135.
7. Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008; 26: 5344-5351.
8. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg. 2007; 246: 183-191.
9. Nash GM, Gimbel M, Shia J, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010; 17: 572-578.
10. Stremitzer S, Stift J, Gruenberger B, et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg. 2012; 99: 1575-1582.
11. Vauthey JN, Zimmitti G, Kopetz S, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013, in press
12. Oudejans JJ, Slebos RJ, Zoetmulder FA, et al. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer. 1991; 49: 875-879.
13. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012; 30: 2956-2962.
14. Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011; 17: 1122-1130.
15. Kawamoto Y, Tsuchihara K, Yoshino T, et al. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer. 2012; 107: 340-344.
16. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009; 101: 715-721.
17. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-762.
18. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011; 117: 4623-4632.
19. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009; 302: 2338-2344.
20. Adams RB, Aloia TA, Loyer E, et al. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013; 15: 91-103.